11月25日 - ** Piper Sandler启动了对Opus Genetics IRD.O的覆盖，给予 "增持 "评级；将目标价定为7美元，与该股上次收盘价相比有约250%的上涨空间
** 处于临床阶段的生物制药公司股价盘前上涨 4.5% 至 2.09 美元
** IRD的主导项目OPGx-LCA5在一种超罕见眼病(LCA5的早期临床数据强劲，券商因此看好IRD。)
** Piper Sandler 注意到该公司如何首先瞄准 LCA5 和 BEST1 等超罕见疾病，因为这些疾病的竞争最小，监管途径通常更快。
** 所有八家券商都将该股评为 "买入 "或更高评级；其PT中值为8美元--数据由LSEG汇编
** 截至上次收盘，IRD股价上涨了约68.1%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.